Compare PSFE & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSFE | AGEN |
|---|---|---|
| Founded | 1996 | 1994 |
| Country | United Kingdom | United States |
| Employees | N/A | 81 |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.3M | 335.6M |
| IPO Year | 2020 | 1999 |
| Metric | PSFE | AGEN |
|---|---|---|
| Price | $5.72 | $6.98 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | $8.50 | ★ $26.33 |
| AVG Volume (30 Days) | 302.6K | ★ 1.0M |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.96 |
| Revenue | N/A | ★ $42,877,086.00 |
| Revenue This Year | $6.51 | $9.64 |
| Revenue Next Year | $5.37 | N/A |
| P/E Ratio | ★ N/A | $7.74 |
| Revenue Growth | N/A | ★ 89.95 |
| 52 Week Low | $5.35 | $2.71 |
| 52 Week High | $12.95 | $10.19 |
| Indicator | PSFE | AGEN |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 40.15 |
| Support Level | $5.35 | $6.51 |
| Resistance Level | $6.83 | $8.64 |
| Average True Range (ATR) | 0.29 | 0.62 |
| MACD | 0.02 | -0.22 |
| Stochastic Oscillator | 28.00 | 5.17 |
Paysafe Ltd is an integrated payments platform. Its core purpose is to enable businesses and consumers to connect and transact seamlessly through capabilities in payment processing, digital wallet, and online cash solutions. The company's reportable segments are Merchant Solutions and Digital Wallets. The Merchant Solutions segment, which derives maximum revenue, services markets in North America, Canada and Europe. The Digital Wallets segment services markets in Europe, UK, North America and Latin America. It derives a majority of revenue from the USA followed by Germany, the UK, and all other countries.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.